Jiangsu Kanion Pharmaceutical Co.,Ltd.’s (SHSE:600557) stock price dropped 6.7% last week; individual investors would not be happy
Key Insights
- Significant control over Jiangsu Kanion PharmaceuticalLtd by individual investors implies that the general public has more power to influence management and governance-related decisions
- A total of 8 investors have a majority stake in the company with 51% ownership
- 22% of Jiangsu Kanion PharmaceuticalLtd is held by Institutions
If you want to know who really controls Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557), then you’ll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are individual investors with 38% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
And following last week’s 6.7% decline in share price,…
